Marinus Pharmaceuticals' Ganaxolone Receives FDA Orphan Drug Designation in PCDH19 Female Epilepsy
25 March 2015
Marinus Pharmaceuticals, Inc.(Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation for ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, for the treatment of protocadherin 19 gene (PCDH19) female epilepsy.
16 March 2015
Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the efficacy and safety results from Clearside’s recently completed six-month Phase 1/2 clinical trial.
Marinus Pharmaceuticals Provides Business Update and Reports Year End 2014 Financial Results
12 March 2015
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative epilepsy and other neuropsychiatric therapeutics, today provided a business update and announced its financial results for the year ended December 31, 2014.
09 March 2015
Epic Sciences and The Prostate Cancer Clinical Trials Consortium (PCCTC), the leading consortium for Phase 1/2 and Phase 2 clinical trials in prostate cancer, announced today they have entered into a collaboration to apply Epic's circulating tumor cell (CTC) technology in multiple investigator-initiated clinical trials to advance the development of new prostate cancer treatments.
Nuvo Research® Provides Business Update
05 March 2015
Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today provided a business update.
02 March 2015
Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the enrollment of the first patient in a Phase 2 randomized, controlled, masked, multi-center clinical trial for the treatment of macular edema associated with retinal vein occlusion (RVO) using Clearside’s proprietary formulation of triamcinolone acetonide, CLS-TA, administered via suprachoroidal (SCS) injection using Clearside’s proprietary microinjector.
Epic Sciences Appoints Chris Bernard as Chief Commercial Officer
25 February 2015
Epic Sciences announced today the appointment of Chris Bernard as chief commercial officer. Mr. Bernard has more than 20 years of experience as a senior executive and company officer leading sales and marketing teams to build biopharma and translational research partnerships and commercialize IVD platforms.
24 February 2015
Epic Sciences announced today that results from studies in metastatic castration resistant prostate cancer (mCRPC), neuroendocrine prostate cancer (NEPC) and muscle-invasive, metastatic bladder cancers using Epic's circulating tumor cell (CTC) technology will be presented at the 2015 ASCO Genitourinary Cancers Symposium which will be held February 26 to 28 at Rosen Shingle Creek in Orlando, Fla.
Atlas Genetics Aims to Bring io Platform to Market This Year after Long Delay
19 February 2015
Initially planned for a 2011 launch, Atlas Genetics' multiplex, molecular diagnostics system, called io, will hit the market four years later if the company is successful in launching it this year.
Syndax CEO Says an Immuno-Oncology Thing Happened on the Way to IPO
18 February 2015
A bull market doesn’t guarantee a successful IPO. Syndax Pharmaceuticals of Waltham, MA, for instance, began preparing for an IPO back nearly a year ago, but it never made its Nasdaq debut.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024